Plasma P-Tau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.
BACKGROUND AND OBJECTIVES Although plasma phosphorylated tau-217 (pTau217) detects co-occurring Alzheimer disease (AD) neuropathologic change in Lewy body disease (LBD), relationships with long-term clinical outcomes remain unclear. Our aim was to evaluate plasma pTau217 as a prognostic, risk-stratification, and monito...